APA (7th ed.) Citation

GP, S., L, S., J, A., DA, S., M, S., A, S., . . . D, C. (2026). Preclinical characterization of AZD1163, a first-in-class anti-PAD2/4 bispecific antibody for the treatment of rheumatoid arthritis. MAbs, 18(1), 2657629. https://doi.org/10.1080/19420862.2026.2657629

Chicago Style (17th ed.) Citation

GP, Sims, et al. "Preclinical Characterization of AZD1163, a First-in-class Anti-PAD2/4 Bispecific Antibody for the Treatment of Rheumatoid Arthritis." MAbs 18, no. 1 (2026): 2657629. https://doi.org/10.1080/19420862.2026.2657629.

MLA (9th ed.) Citation

GP, Sims, et al. "Preclinical Characterization of AZD1163, a First-in-class Anti-PAD2/4 Bispecific Antibody for the Treatment of Rheumatoid Arthritis." MAbs, vol. 18, no. 1, 2026, p. 2657629, https://doi.org/10.1080/19420862.2026.2657629.